bioAffinity Technologies, Inc. announced on October 30, 2024, that it has received a patent award from the Japanese Patent Office for its CyPath® Lung diagnostic test. This patent protects the proprietary method behind the company's noninvasive test for early-stage lung cancer.
The Japanese patent strengthens bioAffinity Technologies' intellectual property portfolio, providing protection for its core technology in a key international market. This is significant for the company's long-term strategy and potential global commercialization efforts.
Securing intellectual property in major economies like Japan is essential for safeguarding the company's competitive position and supporting future market penetration for CyPath® Lung, which aims to improve early detection of lung cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.